Related references
Note: Only part of the references are listed.Antivirals With Activity Against Monkeypox: A Clinically Oriented Review
Emily A. Siegrist et al.
CLINICAL INFECTIOUS DISEASES (2023)
Clinical features and management of human monkeypox: a retrospective observational study in the UK
Hugh Adler et al.
LANCET INFECTIOUS DISEASES (2022)
Targeting F13 from monkeypox virus and variola virus by tecovirimat: Molecular simulation analysis
Daoqun Li et al.
JOURNAL OF INFECTION (2022)
Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States
Wilfredo R. Matias et al.
OPEN FORUM INFECTIOUS DISEASES (2022)
Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection
Angel N. Desai et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat
Loren E Hernandez et al.
LANCET (2022)
Call for a unified approach to Monkeypox infection in pregnancy: Lessons from the COVID-19 pandemic Comment
Asma Khalil et al.
NATURE COMMUNICATIONS (2022)
Clinical management, antiviral drugs and immunotherapeutics for treating monkeypox. An update on current knowledge and futuristic prospects
Sandip Chakraborty et al.
INTERNATIONAL JOURNAL OF SURGERY (2022)
An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications
Andrew T. Russo et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Estimation of Absolute Bioavailability of the Chemical Substance of the Anti-Smallpox Preparation NIOCH-14 in Mice
O. Yu Mazurkov et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2020)
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge
G Yang et al.
JOURNAL OF VIROLOGY (2005)